Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Stoke Therapeutics, Inc. (STOK) had Return on Tangible Equity of 32.24% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$158.57M |
|
$112.88M |
|
-- |
|
$158.57M |
|
$47.33M |
|
$111.24M |
|
$2.92M |
|
$114.16M |
|
$114.16M |
|
$112.88M |
|
$112.88M |
|
$112.88M |
|
$112.88M |
|
$111.24M |
|
$111.22M |
|
57.86M |
|
59.40M |
|
$1.95 |
|
$1.90 |
|
| Balance Sheet Financials | |
$375.74M |
|
$3.61M |
|
$31.15M |
|
$406.89M |
|
$44.69M |
|
-- |
|
$12.13M |
|
$56.81M |
|
$350.07M |
|
$350.07M |
|
$350.07M |
|
54.60M |
|
| Cash Flow Statement Financials | |
$131.83M |
|
$13.63M |
|
$1.37M |
|
$128.78M |
|
$275.61M |
|
$146.83M |
|
$6.75M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.41 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
70.15% |
|
70.15% |
|
-- |
|
71.99% |
|
71.19% |
|
$131.68M |
|
-- |
|
-- |
|
-- |
|
0.39 |
|
-- |
|
261.67 |
|
0.34 |
|
32.24% |
|
|
Return on Tangible Equity |
32.24% |
27.74% |
|
32.24% |
|
$6.41 |
|
$2.22 |
|
$2.22 |
|